CRYAA and lung cancer: Regarding the lung cancer antigens that had a significant diagnostic capability for lung cancer samples: ZNF573, BRAF, TM4SF1, SOX2, IGFBP2, MAGE.A4, BMI1, GAD2, FXR1, HuC, CRYAA, ESO1, the distribution levels of those tested autoantibodies in the lung cancer group and the control group are shown in Figure 4.